| |
|
|
The
Right Choice in FOBTs is E.A.S.Y. |
| |
Hemoccult, the most widely used and trusted brand
in the industry, is proud to announce the arrival
of the latest healthcare advancement - Hemoccult ICT.
It's the most effective FOBT on the market today,
easy to use, and could just be the difference between
life-threatening . . . and life-saving.
The Hemoccult ICT is an immunochemical
FOBT (iFOBT). One advantage of iFOBT is that it
is specific to whole human hemoglobin. The iFOBT
is specific to lower GI bleeding and is not affected
by dietary or medicinal interferences. Thus there
are fewer false positives compared to the traditional
guaiac based FOBTs (gFOBT). This means better healthcare.
|
 |
|
|
Better
Healthcare |
| |
 Clinically
proven immunochemical FOBT
Human
hemoglobin specific means fewer false positives
High
sensitivity and specificity
Detects
lower GI bleeding |
|
|
Improve
Compliance |
| |
No
diet or drug restrictions
Safe,
non-invasive
CLIA
waived with clear readable test results
When it comes to screening for colorectal cancer
everyone deserves the E.A.S.Y
choice.
E ffective- Hemoccult has been
clinically proven to significantly lower the
burden of colorectal cancer by reducing incidence
and mortality.1,2
A ccessible- Designed to screen
large populations of people. Cost effective
and samples can be collected at the patient’s
home.
S afe- Non-invasive.
Y early- Recognized as an effective
CRC screening tool when performed on a yearly
basis.
Hemoccult ICT is the most clinically proven
immunochemical FOBT with high sensitivity and
specificity.3
Immunochemical FOBTs, like Hemoccult ICT, are
now part of the new standard of care for colorectal
cancer screening.4
So do right by your patients and your practice.
Hemoccult ICT - do it for life the E.A.S.Y.
way.
|
|
|
References:
1. Mandel, Jack
S., et al.: “The effect of fecal occult-blood
screening on the incidence of colorectal cancer,”
NEJM. 343:1603-1607, 2000.
2. Pignone M, Rich M, Teutsch SM, et al.: “Screening
for colorectal cancer in adults at average risk:
a summary of the evidence for the U.S. Preventative
Services Task Force.” Ann Int Med 2002;137:132-141.
3. Data on file, Beckman Coulter, Inc., Hemoccult
ICT Product Instructions 2004.
4. Smith RA, Cokkinides V, Eyre HJ.: “American
Cancer Society Guidelines for the Early Detection
of Cancer, 2003.” CA Cancer J Clin 2003;53:27-43.
|
|
|
|
|
|
|
 |
